• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Risks and Benefits of Current and Novel Drugs to Treat Agitation in Alzheimer's Disease
Expert Opin Drug Saf. 2022 Oct 17. doi: 10.1080/14740338.2022.2136162. Online ahead of print.ABSTRACTINTRODUCTION: At present, no pharmacological interventions have been approved for the treatment of agitation in Alzheimer's disease (AD), an important neuropsychiatric symptom that has been linked to increased mortality and greater caregiver burden. Antipsychotics offer some benefit, but increase the risk of adverse events such as falls, extrapyramidal symptoms, stroke, and mortality. Over the past 10 years, several new and repurposed medications have shown promise for treating AD-associated agitation.AREAS COVERED: We revi...
Source: Expert Opinion on Drug Safety - October 17, 2022 Category: Drugs & Pharmacology Authors: Nathan Herrmann Hui Jue Wang Ella Bing Xin Song Kritleen K Bawa Krista L Lanct ôt Source Type: research

Sertraline and Mirtazapine Versus Placebo in Subgroups of Depression in Dementia: Findings From the HTA-SADD Randomized Controlled Trial.
CONCLUSION: Because of the exploratory nature of the analyses and the small sample sizes for subgroup analysis there is the need for caution in interpreting these data. Replication of the potential effects of mirtazapine in the subgroup of those with depression in dementia with "psychological" symptoms would be valuable. These data should not change clinical practice, but future trials should consider stratifying types of depression in dementia in secondary analyses. PMID: 31084994 [PubMed - as supplied by publisher]
Source: The American Journal of Geriatric Psychiatry - May 16, 2019 Category: Psychiatry Tags: Am J Geriatr Psychiatry Source Type: research